- Trials with a EudraCT protocol (14)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
14 result(s) found for: Female ejaculation.
Displaying page 1 of 1.
EudraCT Number: 2009-011855-40 | Sponsor Protocol Number: OTB109059 | Start Date*: 2009-11-26 | |||||||||||
Sponsor Name:GlaxoSmithKline Research and Development Ltd | |||||||||||||
Full Title: A Phase II Study to Evaluate: Delay in Intravaginal Ejaculatory Latency Time (IELT), Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Two Oral Doses of GSK557296 in a Randomized, Doub... | |||||||||||||
Medical condition: Premature ejaculation. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001650-94 | Sponsor Protocol Number: 191622-133 | Start Date*: 2013-08-06 | |||||||||||
Sponsor Name:Allergan Limited | |||||||||||||
Full Title: An Exploratory Study of the Safety and Efficacy of BOTOX® for the Treatment of Premature Ejaculation | |||||||||||||
Medical condition: Premature Ejaculation | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000244-24 | Sponsor Protocol Number: A3871027 | Start Date*: 2004-08-18 | |||||||||||
Sponsor Name:Pfizer AB | |||||||||||||
Full Title: A Phase 2b, multi-center, double-blind, placebo-controlled, parallel group dose response study to assess the efficacy and safety of oral UK-390,957 in men with premature ejaculation. | |||||||||||||
Medical condition: Premature Ejaculation | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: SE (Completed) HU (Completed) IT (Completed) ES (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-011411-21 | Sponsor Protocol Number: BVF-324-302 | Start Date*: 2009-07-17 | |||||||||||
Sponsor Name:Biovail Laboratories International SRL, c/o Biovail Technologies Ltd | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Two Doses of Tramadol Hydrochloride Orally Disintegrating Tablets in Male Subjects with Pre... | |||||||||||||
Medical condition: Premature Ejaculation | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: HU (Prematurely Ended) BG (Prematurely Ended) CZ (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-011410-18 | Sponsor Protocol Number: BVF-324-301 | Start Date*: 2009-07-29 | |||||||||||
Sponsor Name:Biovail Laboratories International SRL, c/o Biovail Technologies Ltd | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Two Doses of Tramadol Hydrochloride Orally Disintegrating Tablets in Male Subjects with Pre... | |||||||||||||
Medical condition: Premature Ejaculation | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: BE (Completed) DE (Prematurely Ended) FR (Completed) SE (Prematurely Ended) ES (Completed) GB (Prematurely Ended) NL (Prematurely Ended) AT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-004150-51 | Sponsor Protocol Number: A3871029 | Start Date*: 2004-12-10 | |||||||||||
Sponsor Name:Pfizer Limited | |||||||||||||
Full Title: A Phase 2 multi centre, double blind, placebo controlled flexible dose study to assess the efficacy and safety of oral UK-390,957 in men with premature ejaculation. | |||||||||||||
Medical condition: Premature Ejaculation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001511-70 | Sponsor Protocol Number: 44313 | Start Date*: 2015-08-05 |
Sponsor Name:Maastricht University Medical Center | ||
Full Title: Efficacy, safety and tolerability of lacosamide in patients with gain-of-function Nav1.7 mutations related small fiber neuropathy: a randomized, double-blind, placebo controlled, crossover trial | ||
Medical condition: SCN9A mutation related small fiber neuropathy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2014-004784-20 | Sponsor Protocol Number: BER-PRO-2014-01 | Start Date*: 2015-01-22 | |||||||||||
Sponsor Name:Instituto Bernabeu | |||||||||||||
Full Title: Subcutaneous progesterone ( Prolutex ) versus vaginal progesterone capsules (Progeffik) for endometrial preparation in fresh donated oocyte recipients: A prospective, randomized, single-blind, pi... | |||||||||||||
Medical condition: Infertility. Assisted Reproductive Techniques. Fresh donated oocyte recipients | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003993-42 | Sponsor Protocol Number: PKB171-02 | Start Date*: 2017-03-17 |
Sponsor Name:Prokrea BCN S.L. | ||
Full Title: A multi-centre, randomised, double-blind, placebo-controlled trial to investigate the efficacy and safety of two concentrations of PKB171 against placebo in couples with asthenozoospermia who wish ... | ||
Medical condition: Asthenozoospermia | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2019-003063-21 | Sponsor Protocol Number: HLX10-005-SCLC301 | Start Date*: 2020-06-17 | |||||||||||
Sponsor Name:Shanghai Henlius Biotech, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Multicenter, Phase III Study to Compare Clinical Efficacy and Safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) in Combination with Chemoth... | |||||||||||||
Medical condition: Extensive Stage Small Cell Lung Cancer (ES-SCLC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000743-31 | Sponsor Protocol Number: 73841937NSC3003 | Start Date*: 2020-09-23 | |||||||||||
Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
Full Title: A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR Mutated Locally Advanced or Metastat... | |||||||||||||
Medical condition: EGFR-mutated locally advanced or metastatic Non Small Cell Lung Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) GB (GB - no longer in EU/EEA) DE (Trial now transitioned) PT (Trial now transitioned) HU (Trial now transitioned) PL (Trial now transitioned) NL (Ongoing) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002226-27 | Sponsor Protocol Number: HLX10-020-SCLC302 | Start Date*: 2022-11-17 | |||||||||||
Sponsor Name:Shanghai Henlius Biotech, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, International Multicenter, Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) or Pla... | |||||||||||||
Medical condition: Patients with Limited-Stage Small Cell Lung Cancer (LS-SCLC) at stage I-III of the AJCC 8th edition of the cancer staging | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) DE (Trial now transitioned) HU (Trial now transitioned) PL (Trial now transitioned) AT (Trial now transitioned) LV (Trial now transitioned) CZ (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000633-40 | Sponsor Protocol Number: 61186372NSC3001 | Start Date*: 2020-11-18 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins-mutated Locally Advanced... | |||||||||||||
Medical condition: EGFR Exon 20ins-mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Trial now transitioned) PT (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003064-50 | Sponsor Protocol Number: HLX10-004-NSCLC303 | Start Date*: 2020-06-17 | |||||||||||
Sponsor Name:Shanghai Henlius Biotech, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Multicenter, Phase III Clinical Study of HLX10 (Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection) + Chemotherapy (Carboplatin-Nanoparticle Albumin-Bound (na... | |||||||||||||
Medical condition: First-Line Therapy for Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
